Termination of Registration of a Class of Security Under Section 12(g) (15-12g)
March 21 2023 - 5:01PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT
OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS
13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number
000-53855
PEAK PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
14201 N. Hayden Road, Suite A-1, Scottsdale, AZ
85260
Telephone: (480) 659-6404
(Address, including zip code, and telephone number,
including area code, of registrant’s principal executive offices)
Common Stock, par value $0.0001 per share
(Title of each class of securities covered by this
Form)
None
(Titles of all other classes of securities for which
a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the
appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
Rule 12g-4(a)(1) |
|
☒ |
Rule 12g-4(a)(2) |
|
☒ |
Rule 12h-3(b)(1)(i) |
|
☐ |
Rule 12h-3(b)(1)(ii) |
|
☐ |
Rule 15d-6 |
|
☐ |
Rule 15d-22(b) |
|
☐ |
Approximate number of holders of record as of the
certification or notice date: 24
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: March 21, 2023
|
|
|
PEAK PHARMACEUTICALS, INC. |
|
|
By: |
|
/s/ Neil Reithinger |
Name: |
|
Neil Reithinger |
Title: |
|
Chief Executive Officer |
2
Peak Pharmaceuticals (PK) (USOTC:PKPH)
Historical Stock Chart
From Apr 2024 to May 2024
Peak Pharmaceuticals (PK) (USOTC:PKPH)
Historical Stock Chart
From May 2023 to May 2024